Topical Immunotherapy: What's New
- 1 April 2005
- journal article
- review article
- Published by Elsevier in Dermatologic Clinics
- Vol. 23 (2) , 245-258
- https://doi.org/10.1016/j.det.2004.08.002
Abstract
No abstract availableKeywords
This publication has 117 references indexed in Scilit:
- Amelanotic lentigo maligna managed with topical imiquimod as immunotherapyJournal of the American Academy of Dermatology, 2004
- Use of Imiquimod Cream 5% in the Treatment of Localized MorpheaJournal of Cutaneous Medicine and Surgery, 2004
- Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trialsJournal of the American Academy of Dermatology, 2004
- Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studiesJournal of the American Academy of Dermatology, 2004
- Utilization of topical steroids and topical immunomodulators in the United StatesJournal of the American Academy of Dermatology, 2004
- Tacrolimus effect on rosaceaJournal of the American Academy of Dermatology, 2004
- Macrolactam immunomodulators for topical treatment of inflammatory skin diseasesJournal of the American Academy of Dermatology, 2001
- The Imidazoquinolines, Imiquimod and R-848, Induce Functional, but Not Phenotypic, Maturation of Human Epidermal Langerhans' CellsClinical Immunology, 2000
- Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% creamJournal of the American Academy of Dermatology, 1999
- Treatment of basal cell carcinoma with intralesional interferonJournal of the American Academy of Dermatology, 1986